Northstrive Biosciences Secures Exclusive EL-22 Animal Health Licensing Deal with Modulant Biosciences

Reuters
05/17
Northstrive Biosciences Secures Exclusive EL-22 Animal Health Licensing Deal with Modulant Biosciences

Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., has announced the signing of a binding term sheet with Modulant Biosciences LLC. This agreement outlines the terms for a future definitive licensing arrangement, granting Modulant exclusive global rights to develop and commercialize EL-22 for animal health applications. This collaboration marks a strategic opportunity for Northstrive to monetize the intellectual property of EL-22, potentially transforming it into a long-term revenue-generating asset. The license allows Modulant to utilize EL-22 in various animal health applications, including as a feed additive, with the exception of the Republic of Korea. Modulant, led by seasoned biotechnology executive Tom Campi, will also have the right to sublicense the technology globally. Financial terms include revenue sharing, where Northstrive will receive a percentage of revenues until a specified limit, after which the royalty rate will decrease. The parties aim to finalize the definitive licensing agreement in the coming months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-044824), on May 16, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10